Skip to main content
Top
Published in: BMC Cancer 1/2021

Open Access 01-12-2021 | Radiotherapy | Research article

Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors

Authors: Rahel Kasteler, Christa Lichtensteiger, Christina Schindera, Marc Ansari, Claudia E. Kuehni, for the Swiss Pediatric Oncology Group (SPOG) Scientific Committee

Published in: BMC Cancer | Issue 1/2021

Login to get access

Abstract

Background

Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer. Chest wall abnormalities are not well-described in the literature, and little is known on the impact on daily life of survivors.

Methods

We investigated prevalence and risk factors of chest wall abnormalities in childhood cancer survivors in a nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey. We then interviewed a nested sample of survivors to validate types of chest wall abnormalities and understand their impact on the daily life of survivors.

Results

Forty-eight of 2382 (95%CI 2–3%) survivors reported a chest wall abnormality. Risk factors were older age at cancer diagnosis (16–20 years; OR 2.5, 95%CI 1.0–6.1), lymphoma (OR 3.8, 95%CI 1.2–11.4), and central nervous system tumors (OR 9.5, 95%CI 3.0–30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0, 95%CI 1.0–4.2), surgery to the chest (OR 4.5, 95%CI 1.8–11.5), or chemotherapy (OR 2.9, 95%CI 1.0–8.1). The nature of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%) or both (55%), and scars (10%). Chest wall abnormalities affected daily life in two thirds (13/20) of those who reported these problems and necessitated medical attention for 15 (75%) survivors.

Conclusion

It is important that, during follow-up care, physicians pay attention to chest wall abnormalities, which are rare late effects of cancer treatment, but can considerably affect the well-being of cancer survivors.
Appendix
Available only for authorised users
Literature
3.
go back to reference Trobs RB, Hansel M, Friedrich T, Bennek J. A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg. 2001;11(2):92–8.CrossRef Trobs RB, Hansel M, Friedrich T, Bennek J. A 23-year experience with malignant renal tumors in infancy and childhood. Eur J Pediatr Surg. 2001;11(2):92–8.CrossRef
6.
go back to reference Butler MS, Robertson WW Jr, Rate W, D'Angio GJ, Drummond DS. Skeletal sequelae of radiation therapy for malignant childhood tumors. Clin Orthop Relat Res. 1990;251:235–40. Butler MS, Robertson WW Jr, Rate W, D'Angio GJ, Drummond DS. Skeletal sequelae of radiation therapy for malignant childhood tumors. Clin Orthop Relat Res. 1990;251:235–40.
7.
go back to reference Taylor RE. Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. United Kingdom Children's Cancer Study Group. Clin Oncol (Royal College of Radiologists (Great Britain)). 1997;9(6):381–4.CrossRef Taylor RE. Morbidity from abdominal radiotherapy in the First United Kingdom Children's Cancer Study Group Wilms' Tumour Study. United Kingdom Children's Cancer Study Group. Clin Oncol (Royal College of Radiologists (Great Britain)). 1997;9(6):381–4.CrossRef
9.
go back to reference Utriainen P, Vatanen A, Toiviainen-Salo S, Saarinen-Pihkala U, Mäkitie O, Jahnukainen K. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue. Bone Marrow Transplant. 2017;52(5):711–6. https://doi.org/10.1038/bmt.2016.345. Epub 2017 Jan 9. Utriainen P, Vatanen A, Toiviainen-Salo S, Saarinen-Pihkala U, Mäkitie O, Jahnukainen K. Skeletal outcome in long-term survivors of childhood high-risk neuroblastoma treated with high-dose therapy and autologous stem cell rescue. Bone Marrow Transplant. 2017;52(5):711–6. https://​doi.​org/​10.​1038/​bmt.​2016.​345. Epub 2017 Jan 9.
12.
go back to reference Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, Ammann RA, Kuehni CE, Swiss Pediatric Oncology Group (SPOG). Longterm pulmonary disease among Swiss childhood cancer survivors. Pediatr Blood Cancer. 2018;65(1). https://doi.org/10.1002/pbc.26749. Epub 2017 Sep 4. Kasteler R, Weiss A, Schindler M, Sommer G, Latzin P, von der Weid NX, Ammann RA, Kuehni CE, Swiss Pediatric Oncology Group (SPOG). Longterm pulmonary disease among Swiss childhood cancer survivors. Pediatr Blood Cancer. 2018;65(1). https://​doi.​org/​10.​1002/​pbc.​26749. Epub 2017 Sep 4.
13.
go back to reference Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss childhood Cancer registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly. 2007;137(35–36):502–9. Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE. The Swiss childhood Cancer registry: rationale, organisation and results for the years 2001-2005. Swiss Med Wkly. 2007;137(35–36):502–9.
16.
19.
go back to reference Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M. Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. Clin Cases Miner Bone Metab. 2013;10(3):172–9. Stagi S, Cavalli L, Iurato C, Seminara S, Brandi ML, de Martino M. Bone metabolism in children and adolescents: main characteristics of the determinants of peak bone mass. Clin Cases Miner Bone Metab. 2013;10(3):172–9.
Metadata
Title
Validation of questionnaire-reported chest wall abnormalities with a telephone interview in Swiss childhood cancer survivors
Authors
Rahel Kasteler
Christa Lichtensteiger
Christina Schindera
Marc Ansari
Claudia E. Kuehni
for the Swiss Pediatric Oncology Group (SPOG) Scientific Committee
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Radiotherapy
Published in
BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-021-08425-z

Other articles of this Issue 1/2021

BMC Cancer 1/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine